<DOC>
	<DOCNO>NCT01863160</DOCNO>
	<brief_summary>It phase I randomize , double blind , placebo-controlled , dose-escalating study ass safety , tolerability pharmacokinetics ( PK ) data 0.1 % 1.0 % ZEP-3 cream , administer topically 5 consecutive treatment day healthy volunteer . This single center trial . It anticipate study conduct Department Dermatology , Sheba Medical Center , Ramat Gan , Israel . The screening/enrollment visit include PK study 24h follow single IP topical application . After 24h washout time break , subject enter treatment period 5 consecutive treatment day follow follow visit 1 5 day end treatment .</brief_summary>
	<brief_title>Safety Tolerability Study ZEP-3 Cream ( 0.1 % 1.0 % ) , Administered Topically In Healthy Volunteers</brief_title>
	<detailed_description>The primary endpoint study : - Safety evaluation - To demonstrate ZEP-3 cream safety term skin irritation score . - Safety evaluation - To demonstrate ZEP-3 cream safety term type severity report adverse event . - Tolerability evaluation - To demonstrate ZEP-3 cream tolerability term treatment compliance treat volunteer . The secondary endpoint study : - Systemic absorption PK profile . - Dermal absorption PK profile ( Optional ) . Subject safety assess follow treatment ZEP-3 cream , use measurement follow variable : - Dermal reaction parameter - Physical examination - Vital Signs ( HR , BP , RR , Body temperature ) - 12 lead ECG data - Laboratory test ( CBC , blood chemistry , coagulation function , urinalysis ) - Adverse event record - Change concomitant medication</detailed_description>
	<criteria>1 . Subject must voluntarily sign date write Informed Consent prior study specific procedure 2 . Subject , either men woman 18 50 year age . 3 . Subject , Body mass index ( BMI ) within normal overweight range ( See appendix 2 ) 4 . Subject must healthy skin redden easily recognize area place test article 5 . Subject must free condition/disease investigator feel interfere interpretation study result . 6 . Subject willing participate study adhere study protocol 7 . Females childbearing potential either surgically sterile , use highly effective medically accept contraceptive regimen . 1 . Subject hyper hypopigmentation , tattoos area place test field 2 . Dark skin person whose skin color prevents ready assessment skin reaction 3 . Subject history skin disorder active skin condition involve test field include limited bacterial , viral , fungal skin infection , acne , rosacea 4 . UV therapy significant UV exposure four week treatment application 5 . Subject renal failure ( Cr &gt; 2 mg/dl ) Subject impair hepatic function ( ALT , AST 2fold high normal upper limit value ) . 6 . Cardiac disease , include recent myocardial infarction , degree heart block cardiac arrhythmia valvular heart disease 7 . Subject suffers autoimmune disease ( Diabetes , Lupus . Chron ect . ) 8 . History malignancy 9 . Sever illness surgery within previous 3 month ( except minor cosmetic dental procedure ) 10 . Treatment investigational agent another clinical trial within 1 month prior start study . 11 . Female subject pregnant , lactating , positive pregnancy test 12 . History drug alcohol abuse ( define Investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetic profile</keyword>
	<keyword>ZEP-3 Cream ( 0.1 % 1.0 % )</keyword>
	<keyword>administer topically</keyword>
</DOC>